Table 1. Epidemiology of IFDs from... | American Society of Hematology

Table 1.

Epidemiology of IFDs from select pediatric leukemia cohorts

Author, year	Study design	Patient type	Antifungal prophylaxis	IFD definition	IFD incidence
AML
Sung et al¹	Summary of adverse event data from chemotherapy RCT	Newly diagnosed AML	Not routinely used	Not specified	18% to 23% incidence per chemotherapy course
Fisher et al²	RCT of 2 antifungal prophylaxis regimens	De novo, secondary, or relapsed AML	Fluconazole or caspofungin	2008 EORTC/MSG criteria³³	3.1% in caspofungin subjects^; 7.2% in fluconazole subjects^
ALL
Rosen et al⁴	Retrospective single-center observational cohort	Any type of newly diagnosed ALL	Not routinely used	Not specified	10%^†
Wang et al⁷	Retrospective multicenter observational cohort	Reported by ALL type and risk strata	Varied by health care center	2008 EORTC/MSG criteria³³	6.2% overall^†; 5.8% SR ALL^†; 8.7% HR ALL^†; 3.8% nonrelapsed ALL^†; 12.9% relapsed refractory ALL^†
Castagnola et al⁶	Retrospective single-center observational cohort	Any type of newly diagnosed ALL	Not routinely used	2008 EORTC/MSG criteria³³	5.4% overall^†; 15.2% HR ALL^†

Author, year	Study design	Patient type	Antifungal prophylaxis	IFD definition	IFD incidence
AML
Sung et al¹	Summary of adverse event data from chemotherapy RCT	Newly diagnosed AML	Not routinely used	Not specified	18% to 23% incidence per chemotherapy course
Fisher et al²	RCT of 2 antifungal prophylaxis regimens	De novo, secondary, or relapsed AML	Fluconazole or caspofungin	2008 EORTC/MSG criteria³³	3.1% in caspofungin subjects^; 7.2% in fluconazole subjects^
ALL
Rosen et al⁴	Retrospective single-center observational cohort	Any type of newly diagnosed ALL	Not routinely used	Not specified	10%^†
Wang et al⁷	Retrospective multicenter observational cohort	Reported by ALL type and risk strata	Varied by health care center	2008 EORTC/MSG criteria³³	6.2% overall^†; 5.8% SR ALL^†; 8.7% HR ALL^†; 3.8% nonrelapsed ALL^†; 12.9% relapsed refractory ALL^†
Castagnola et al⁶	Retrospective single-center observational cohort	Any type of newly diagnosed ALL	Not routinely used	2008 EORTC/MSG criteria³³	5.4% overall^†; 15.2% HR ALL^†

5-month cumulative incidence.

^†

Cumulative incidence for duration of chemotherapy.

CTCAE, common terminology criteria for adverse events; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; IFD, invasive fungal disease; RCT, randomized controlled trial.

View Large

This Feature Is Available To Subscribers Only